Intensity-Modulated Radiation Therapy for the Treatment of Squamous Cell Anal Cancer With Para-aortic Nodal Involvement

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 3, 2009, Pages 791-794

  Hodges, Joseph C ^a   Das, Prajnan ^a   Eng, Cathy ^a   Reish, Andrew G ^a   Beddar, A Sam ^a   Delclos, Marc E ^a   Krishnan, Sunil ^a   Crane, Christopher H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anal cancer; Chemoradiation; Intensity modulated radiotherapy; Para aortic lymph node

Indexed keywords

5-FLUOROURACIL; ADJUVANT CHEMOTHERAPY; ANAL CANCER; CHEMORADIATION; CIS-PLATIN; CONCURRENT CHEMOTHERAPY; DEFINITIVE THERAPY; DISTANT METASTASIS; FAILURE RATE; GASTROINTESTINAL TOXICITIES; INGUINAL LYMPH NODES; INTENSITY MODULATED RADIATION THERAPY; INTENSITY-MODULATED RADIOTHERAPY; LOCOREGIONAL CONTROL; NODAL REGION; OVERALL SURVIVAL RATES; PARA-AORTIC LYMPH NODE;

BODY FLUIDS; CELL MEMBRANES; CHEMOTHERAPY; CONCURRENCY CONTROL; PHYSICAL THERAPY; PLATINUM COMPOUNDS; RADIOTHERAPY; TOXICITY; TUMORS;

BLOOD VESSELS;

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ANEMIA; ANUS CANCER; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DIARRHEA; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INGUINAL LYMPH NODE; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PANCYTOPENIA; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROCTITIS; RADIATION DOSE; SMALL INTESTINE OBSTRUCTION; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; AORTA, ABDOMINAL; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70349514764     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.11.021     Document Type: Article

References (20)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Haddock M.G., and Martenson J.A. Anal carcinoma. In: Gunderson L.L., and Tepper J.E. (Eds). Clinical radiation oncology. 2nd ed (2006), Churchill Livingston, Philadelphia 1145-1159
3. Longo W.E., Vernava A.M., Wade T.P., et al. Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy. Ann Surg 220 (1994) 40-49
4. Klas J.V., Rothenberger D.A., Wong W.D., et al. Malignant tumors of the anal canal: The spectrum of disease, treatment, and outcomes. Cancer 85 (1999) 1686-1693
5. Das P., Crane C.H., Eng C., et al. Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res 2 (2008) 10-14
6. In: Greene F.L., Page D.L., Flemming I.D., et al. (Eds). AJCC cancer staging handbook. 6th ed (2002), Sprhinger-Verlag, New York
7. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: Current status and issues of interest. Int J Radiat Oncol Biol Phys 51 (2001) 880-914
8. Chen Y.J., Liu A., Tsai P.T., et al. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: Dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys 63 (2005) 274-281
9. Milano M.T., Jani A.B., Farrey K.J., et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: Toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 63 (2005) 354-361
10. Salama J.K., Mell L.K., Devisetty K., et al. Concurrent chemotherapy and intensity modulated radiation therapy for anal cancer patients: A multicenter experience. J Clin Oncol 26 (2007) 4581-4586
11. Yang W.T., Lam W.W., Yu M.Y., et al. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. AJR Am J Roentgenol 175 (2000) 759-766
12. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
13. James R., Meadows H., and Wan S. ACT II: The second UK phase III anal cancer trail. Clin Oncol (R Coll Radiol) 17 (2005) 364-366
14. Baglan K.L., Frazier R.C., Yan D., et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 52 (2002) 176-183
15. Tho L.M., Glegg M., Paterson J., et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 66 (2006) 505-513
16. Hung A., Crane C., Delclos M., et al. Cisplatin-based combined modality therapy for anal carcinoma: A wider therapeutic index. Cancer 97 (2003) 1195-1202
17. Ajani J.A., Winter K.A., Gunderson L.L., et al. Fluorouracil, mitomycin and radiotherapy vs fluouracil, cisplatin and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 299 (2008) 1914-1921
18. Trautmann T.G., and Zuger J.H. Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 7 (2005) 309-313
19. Cotter S.E., Grigsby P.W., Siegel B.A., et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 65 (2006) 720-725
20. Nguyen B.T., Joon D.L., Khoo V., et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol 87 (2008) 376-382